No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 30-36

  Purkins, Lynn ^a   Wood, Nolan ^a   Ghahramani, Parviz ^a   Kleinermans, Diane ^b   Layton, Gary ^a   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Azithromycin; Erythromycin; Interaction; Pharmacokinetics; Voriconazole

Indexed keywords

AZITHROMYCIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; VORICONAZOLE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSPEPSIA; ERUCTATION; FLATULENCE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VISUAL DISORDER;

EID: 0344081226     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01996.x     Document Type: Article

References (14)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F79, September 1995.
10. von Rosenstiel N-A, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Safety 1995; 13: 105-122.
11. Hoepelman M, Schneider MME. Azithromycin - the first of the tissue-selective azalides. Int J Antimicrob Agents 1995; 5: 145-167.
12. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
13. Wedlund PJ, Wilkinson GR. In vivo and in vitro measurement of CYP2C19 activity. Methods Enzymol 1996; 272: 105-114.
14. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Safety 1999; 20: 25-41.